Cadapersen

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameCadapersen
Drug Alias NamePD-L1 LNA (Roche)PDCD1L1 antisense oligonucleotide therapy (Roche)RG-6084RO-7191863
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProgrammed death-ligand 1 modulators
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsHepatitis B, ChronicHepatitis B
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaTaiwan +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesF. Hoffmann-La Roche Ltd
Inactive CompaniesN/A
Active IndicationsHepatitis B, ChronicHepatitis B
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A